

10562949a

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10562949c.str



chain nodes :

7 8 13 14 15 21 22

ring nodes :

1 2 3 4 5 6 9 10 11

ring/chain nodes :

16

chain bonds :

1-7 4-8 10-21 13-14 14-15 15-16 21-22

ring bonds :

1-6 1-2 2-3 2-9 3-4 3-11 4-5 5-6 9-10 10-11

exact/norm bonds :

1-6 1-2 1-7 2-3 2-9 3-4 3-11 4-5 4-8 5-6 9-10 10-11 10-21 13-14 14-15
15-16 21-22

isolated ring systems :

containing 1 :

G1:O,S

Karen Cheng

10562949a

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 19:CLASS 21:CLASS 22:Atom

L4 STRUCTURE UPLOADED

=> d

L4 HAS NO ANSWERS

L4 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 08:27:36 ON 27 MAR 2007)

FILE 'REGISTRY' ENTERED AT 08:27:44 ON 27 MAR 2007

L1 STRUCTURE UPLOADED

L2 211 S L1 FULL

FILE 'CAPLUS' ENTERED AT 08:28:11 ON 27 MAR 2007

L3 10 S L2

FILE 'REGISTRY' ENTERED AT 08:40:34 ON 27 MAR 2007

L4 STRUCTURE UPLOADED

=> s 14 full sub = 12

FULL SUBSET SEARCH INITIATED 08:40:56 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 211 TO ITERATE

100.0% PROCESSED 211 ITERATIONS
SEARCH TIME: 00.00.01

135. ANSWERS

L5 135 SEA SUB=L2 SSS FUL L4

Karen Cheng

10562949a

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
41.10	266.58

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-7.80

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 08:41:00 ON 27 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Mar 2007 VOL 146 ISS 14

FILE LAST UPDATED: 26 Mar 2007 (20070326/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 15

L6 6 L5

=> d ibib abs hitstr tot

10562949a

Date = 6/25/03
to beat

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:606044 CAPLUS
 DOCUMENT NUMBER: 145:58195
 TITLE: Phosphatase Cdc25 inhibitors and their use in treatment of diseases
 INVENTOR(S): Galcera, Marie Odile; Bigg, Dennis; Prevost, Gregoire; Sidhu, Alban
 PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'Applications Scientifiques Sclas, Fr.
 SOURCE: Fr. Demande, 50 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2879598	A1	20060623	FR 2004-13456	20041217
WO 2006067311	A2	20060629	WO 2005-FR3161	20051216
WO 2006067311	A3	20060817		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BV, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KH, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZH, ZV, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: MARPAT 145:58195 FR 2004-13456 A 20041217

AB Comps. comprising 2 or 3 benzothiazole-4,7-dione or benzoxazole-4,7-dione moieties which inhibit phosphatase Cdc25, especially phosphatase Cdc25-C, are disclosed. These comps. may be used in the treatment of cancer. Thus, 16 comps. of the invention were synthesized. Most inhibited recombinant Cdc25-C with IC50 ≤ 1 μM.


IT 890649-39-5P 890649-40-8P 890649-41-9P
 890649-42-0P 890649-43-1P 890649-44-2P
 890649-45-3P 890649-46-4P 890649-47-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (phosphatase Cdc25 inhibitors and their use in treatment of diseases)

RN 890649-39-5 CAPLUS
 CN 4,7-Benzoxazolidione, 6,6'-[(methylimino)bis(3,1-propanediylimino)]bis[2-(2,5-difluorophenyl)]- (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 890649-42-0 CAPLUS
 CN 4,7-Benzoxazolidione, 6,6'-[(methylimino)bis(3,1-propanediylimino)]bis[2-(3-bromophenyl)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 890649-43-1 CAPLUS
 CN 4,7-Benzoxazolidione, 6,6'-[(methylimino)bis(3,1-propanediylimino)]bis[2-(4-bromophenyl)]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 890649-40-8 CAPLUS
 CN 4,7-Benzoxazolidione, 6,6'-[(methylimino)bis(3,1-propanediylimino)]bis[2-(3,5-dibromophenyl)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 890649-41-9 CAPLUS
 CN 4,7-Benzoxazolidione, 6,6'-[(methylimino)bis(3,1-propanediylimino)]bis[2-[(2-chloro-6-fluorophenyl)methyl]]- (9CI) (CA INDEX NAME)


PAGE 1-A



L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 890649-44-2 CAPLUS
 CN 4,7-Benzoxazolidione, 6,6'-[(methylimino)bis(3,1-propanediylimino)]bis[2-(3,5-difluorophenyl)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 890649-45-3 CAPLUS
 CN 4,7-Benzoxazolidione, 6,6'-[(methylimino)bis(3,1-propanediylimino)]bis[2-(3-chlorophenyl)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 890649-46-4 CAPLUS
 CN 4,7-Benzoxazolidione, 6,6'-[(methylimino)bis(3,1-propanediylimino)]bis[2-(4-fluorophenyl)]- (9CI) (CA INDEX NAME)

10562949a

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 890649-47-5 CAPLUS

CN 4,7-Benzoxazolidione, 6,6'-bis-[(methylimino)bis(3,1-propanediylimino)]bis[2-(4-bromo-3-methylphenyl)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1241413 CAPLUS

DOCUMENT NUMBER: 144:128904

TITLE: Synthesis and biological evaluation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C

AUTHOR(S): Lavergne, Olivier; Fernandes, Anne-Cécile; Brehu, Laetitia; Sidhu, Alban; Brezak, Marie-Christine; Prevost, Gregoire; Ducommun, Bernard; Contour-Galceras, Marie-Odile

CORPORATE SOURCE: Ipsen Research Laboratories, Institut Henri Beaufour, Les Ulis, 91960, Fr.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(1), 171-175

CODEN: BMCLEB; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 144:128904

AB A focused set of heterocyclic quinones based on the benzothiazole, benzoxazole, benzimidazole, indazole and isoindole nucleus was prepared and screened with respect to the inhibition of the phosphatase activity of CDC25C. Benzoxazole- and benzothiazolodiones were 2-50 times more potent in inhibiting CDC25C than their benzimidazole, indazole, or isoindole counterparts. These in vitro activities were in good correlation with the anti-proliferative effects observed with Mia PaCa-2 and DU-145 human tumor cell cultures. The IC50 values obtained by WST-1 colorimetric assay ranged from 0.10 to 0.50 μM for the benzoxazole- or benzothiazole-diones and were > 10 μM for the other heterocyclic diones. This study further illustrates how the activity of the quinone pharmacophore can be selectively modulated by changing the type of five-membered heterocycle fused to the quinone ring.

IT 558475-05-1P 558475-06-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C)

RN 558475-05-1 CAPLUS

CN 4,7-Benzoxazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-phenyl- (9CI) (CA INDEX NAME)



RN 558475-06-2 CAPLUS

CN 4,7-Benzoxazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:124649 CAPLUS

DOCUMENT NUMBER: 142:336281

TITLE: Regioselective preparation of 5-amino- and 6-amino-1,3-benzoxazole-4,7-diones from symmetrical diaminophenol and aminoresorcinol

AUTHOR(S): Brehu, Laetitia; Fernandes, Anne-Cécile; Lavergne, Olivier

CORPORATE SOURCE: Ipsen Research Laboratories, Institut Henri Beaufour, Les Ulis, 91960, Fr.

SOURCE: Tetrahedron Letters (2005), 46(9), 1437-1440

CODEN: TETLEA; ISSN: 0040-4039

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:336281


AB Regioisomeric 5-amino- and 6-amino-1,3-benzoxazole-4,7-diones were prepared from 2,6-diamino-4-methoxyphenol and 2-amino-5-methoxyresorcinol, resp. These sym. precursors have the property to be antisym. to each other with respect to their amino and hydroxy substituents.

IT 558475-35-7P 558475-36-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of regioisomeric 5-amino- and 6-amino-1,3-benzoxazole-4,7-diones from 2,6-diamino-4-methoxyphenol and 2-amino-5-methoxyresorcinol)


RN 558475-35-7 CAPLUS

CN 4,7-Benzoxazolidione, 2-[(3-bromophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-36-8 CAPLUS

CN 4,7-Benzoxazolidione, 2-[(3-bromophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Karen Cheng

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2005:610 CAPLUS

DOCUMENT NUMBER: 142:93811

TITLE: Preparation of pharmaceutical compositions containing at least a Cdc25 phosphatase inhibitor, in particular benzothiazole-4,7-dione, benzoxazole-4,7-dione derivatives, naphthoquinones, and related compounds, combined with at least another anticancer agent for therapeutic use in cancer treatment

INVENTOR(S): Prevost, Gregoire; Brezak Pannetier, Marie Christine

PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques SCRAS, Fr.

SOURCE: Fr. Demande, 135 pp.

CODEN: FROXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2856688	A1	20041231	FR 2003-7649	20030625
CA 2530668	A1	20050106	CA 2004-2530668	20040624
WO 2005000852	A2	20050106	WO 2004-FR1586	20040624
WO 2005000852	A3	20050630		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BV, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RU, SC, SD, SE, SG, SI, SL, SY, TH, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, KZ, NA, SD, SL, SZ, TZ, UG, ZW, MM, AZ, BY, BG, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RU, SC, SD, SE, SG, SI, SL, SY, TH, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
EP 1641453	A2	20060405	EP 2004-767442	20040624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK	A1	20061214	US 2006-562625	20060301
US 2006281736			FR 2003-7679	A 20030625
PRIORITY APPL. INFO:			WO 2004-FR1586	W 20040624

OTHER SOURCE(S): MARPAT 142:93811

G1

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention concerns a product which comprises two components (1) at least one heterocyclic dione I wherein: R1 = H, alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, (CH2)-X or (CH2)-NR5R6, indanyl, tetralinyl, (un)substituted saturated N/O/S heterocyclyl bound at C; also (when W = O) R1 = (un)substituted aryl; R2 = H, halo, alkyl, aralkyl, or NR1R2 may form a heterocyclic ring; R3 = H, halo, alkyl, haloalkyl, alkoxy,

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

alkylthio, R4 = alkyl, cycloalkyl, cycloalkylalkyl, cyano, amino, CH2CO2H or alkyl esters, CH2CONH2 or CH2NH2 or derivs., (un)substituted aryl or heteroaryl; R5, R6 = H, alkyl, aralkyl, or (CH2)nOH in which n = 1-6; or R5 = alkoxyalkyl, haloalkoxyalkyl, or haloalkoxyalkyl, and R6 = H or Me; or NR5R6 = satd., (un)substituted N-heterocycle; X, Z = alkylene; Y = satd., (un)substituted mono-, di-, or tricyclic carbo- or N/O/S heterocycle, or (un)substituted carbo- or heterocyclic aryl; and W = O or S; or A-B-N(W)-X-Y [A = (un)substituted Ph, naphthyl; B = CO, NHCO, CH2N, (CH2)p; n = 0-3; p = 0-1; W = H, alkyl; X = (CH2)q, (CH2)qNH, CO, CH2; q = 1-6; r = 0-6; or N(W)-X = (un)substituted piperazine; Y = (un)substituted Ph, SO2-alkyl, SO2-haloalkyl, etc.] and their pharmaceutically acceptable salts, combined with (2) at least one other anticancer agent for simultaneously, sep. or prolonged therapeutic use in cancer treatment. Specifically, 1 is combined with (a) DNA base analogs, e.g. 5-fluorouracyl; (b) topoisomerase type I and/or II inhibitors, e.g. camptothecin and analogs, doxorubicin, or ansaricins; (c) compds. interacting with the cellular spindle, e.g. Taxol; (d) compds. acting on the cytoskeleton, e.g. vinblastin; (e) G heterotrimeric protein inhibitors II [X = R12; Y = R8; or X and Y may form a 6-membered ring with X-Y = CH(R8)-CH(R9); R1 = H, alkyl, cycloalkylthio; R2, R3 = independently H, cycloalkyl; R4 = H2, O; R5 = H, (un)substituted alk(en)ynyl, cycloalk(en)ynyl, aryl, etc.; R6, R7 = H, (un)substituted alk(en)ynyl, cycloalk(en)ynyl, heterocyclyl, etc.; R8, R9 = independently H, (un)substituted aryl, heterocyclyl, etc.; R12 = NR9, S, O; and their pharmaceutically acceptable salts]; (f) prenyltransferase, esp. farnesyltransferase inhibitors III [A = (CR10)n1; n10 = 0-1; X = (CH2)n3(CH2)n4(CH2)n5; Z = O, S, NH and derivs.; n3 = 0-1; n4, n5 = independently 0-3; Y = CO, CH2, CS, or a bond; R1 = (un)substituted imidazol-5-yl, 1,2,3-triazolyl, pyridinyl, etc.; R3 = H, alkyl, aryl, heterocyclyl, etc.; R4, R5 = independently H, (un)substituted cycloalkyl, aryl, heterocyclyl, or R4CR5 = aryl; R6 = H, (un)substituted alkyl, aryl, aralkyl, etc.; R7 = H, O, S, (un)substituted cycloalkyl, aryl, heterocyclyl, etc.; R10 = C; R11 = H, (un)substituted alkyl, aryl and their pharmaceutically acceptable salts]. I is also combined with (g) CDK inhibitors IV [A = H, halo, formyl, CN, NO2, etc.; X = H, alkylthio, alkylthio, etc.; Y = NH, O = a bond, alkylthio/alkyl; Ar = (un)substituted arylcarboxyl, arylheterocyclyl, and their pharmaceutically acceptable salts]; (h) alkylation agents, e.g. cisplatin; (i) folic acid antagonists, e.g. methotrexate; and (j) inhibitors of DNA synthesis and cellular division, e.g. mitomycin. Nearly 200 Cdc25 phosphatase inhibitors are prepd. and 20 assocns. tested for their antiproliferative activity. Thus, W-HCl (138-140) was prepd. in 2 steps from N,N-dimethylethylamine and 5-methoxy-2-methyl-4,7-dioxobenzothiazole. Most compds. I inhibited the phosphatase activity of purified recombinant Cdc25-C in vitro with IC50 values of ≤ 10 μ M. Most compds. had IC50 values of ≤ 10 μ M against proliferation of human cancer cell lines Hs-Pac2 and DU-145 in vitro. W-HCl was tested for cell proliferation inhibition activity [only 14 of cells lived when combined with VI (vs. colon cancer HT-29 cells)].


IT 817553-15-4P, 2-(2-Chloro-6-fluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Cdc25 inhibitor; preparation and pharmaceutical compns. of

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

benzothiazole-diones, benzoxazole-diones, and analogs for use in chemotherapy

RN 817553-15-4 CAPLUS

CN 4,7-Benzothiazole-dione, 2-(2-chloro-6-fluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



IT 558475-05-1P, 5-[[2-(Dimethylamino)ethyl]amino]-2-phenyl-1,3-benzoxazole-4,7-dione 558475-06-2P, 6-[[2-(Dimethylamino)ethyl]amino]-2-phenyl-1,3-benzoxazole-4,7-dione 558475-09-5P, 2-(2,6-Difluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-10-8P, 2-(2,6-Difluorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-11-9P, 2-(4-(Dimethylamino)phenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-12-0P, 2-(4-(Dimethylamino)phenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-13-1P, 2-(4-(Dimethylamino)phenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-14-2P, 2-(4-(Dimethylamino)phenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-15-3P, 2-(4-Chlorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-16-4P, 2-(4-Chlorophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-17-5P, 2-(4-Chlorophenyl)-5-[[3-(dimethylamino)propyl]amino]-1,3-benzoxazole-4,7-dione 558475-18-6P, 2-(4-Chlorophenyl)-6-[[3-(dimethylamino)propyl]amino]-1,3-benzoxazole-4,7-dione 558475-21-1P, 2-(2-Fluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-22-2P, 2-(2-Fluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-23-3P, 2-(2-Fluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-24-4P, 2-(2-Fluorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-25-5P, 2-(2-Bromophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-26-6P, 2-(2-Bromophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-27-7P, 2-(2-Bromophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-28-8P, 2-(2-Bromophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-29-9P, 2-(2-Bromophenyl)-5-[[3-(dimethylamino)propyl]amino]-1,3-benzoxazole-4,7-dione 558475-30-0P, 2-(2-Bromophenyl)-6-[[3-(dimethylamino)propyl]amino]-1,3-benzoxazole-4,7-dione 558475-31-1P, 2-(2-Chlorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-32-2P, 2-(2-Chlorophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-33-3P, 2-(2-Chlorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-34-4P, 2-(2-Chlorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-35-5P, 2-(3-Bromophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-36-6P, 2-(3-Bromophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-37-7P

Karen Cheng

16 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
2 (3,4-trifluorophenyl)-1,3-benzoxazole-4,7-dione 558476-45-2P,
6-[[2-(Dimethylamino)ethyl]amino]-2-(2,3,4-trifluorophenyl)-1,3-
benzoxazole-4,7-dione 558476-46-3P, 5-[[2-(Pyrrrolidin-1-
yl)ethyl]amino]-2-(2,3,4-trifluorophenyl)-1,3-benzoxazole-4,7-dione
558476-47-4P, 6-[[2-(Pyrrrolidin-1-yl)ethyl]amino]-2-(2,3,4-
trifluorophenyl)-1,3-benzoxazole-4,7-dione 558476-48-5P,
2-(3-Fluoro-4-methylphenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-
benzoxazole-4,7-dione 558476-49-6P, 2-(3-Fluoro-4-methylphenyl)-
6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione
558476-50-9P, 2-(3-Fluoro-4-methylphenyl)-5-[[2-(pyrrolidin-1-
yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558476-51-0P,
2-(3-Fluoro-4-methylphenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-
benzoxazole-4,7-dione 558476-52-1P, 2-(4-Chlorophenyl)-5-[[2-
(dimethylamino)ethyl]amino]-1,3-benzothiazole-4,7-dione
558476-53-2P, 2-(4-Chlorophenyl)-6-[[2-(dimethylamino)ethyl]amino]-
1,3-benzothiazole-4,7-dione 558476-54-3P, 2-(4-Chlorophenyl)-5-
[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzothiazole-4,7-dione
558476-55-4P, 2-(4-Chlorophenyl)-6-[[2-(pyrrolidin-1-
yl)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-56-5P,
5-[[2-(Dimethylamino)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)-1,3-
benzothiazole-4,7-dione 558476-57-6P, 6-[[2-
(Dimethylamino)ethyl]amino]-2-(2,3,5-tetrafluorophenyl)-1,3-
benzothiazole-4,7-dione 558476-58-7P, 5-[[2-
(Dimethylamino)ethyl]amino]-2-(3,4,5-trifluorophenyl)-1,3-benzothiazole-
4,7-dione 558476-59-8P, 6-[[2-(Dimethylamino)ethyl]amino]-2-
(3,4,5-trifluorophenyl)-1,3-benzothiazole-4,7-dione 558476-60-1P,
5-[[2-(Pyrrrolidin-1-yl)ethyl]amino]-2-(2,4,6-trifluorophenyl)-1,3-
benzothiazole-4,7-dione 558476-61-2P, 6-[[2-(Pyrrrolidin-1-
yl)ethyl]amino]-2-(2,4,6-trifluorophenyl)-1,3-benzothiazole-4,7-dione
558476-64-5P, 2-(4-Ethylphenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-
benzoxazole-4,7-dione 558476-65-6P, 6-[[2-
(Dimethylamino)ethyl]amino]-2-(4-Ethylphenyl)-1,3-benzoxazole-4,7-dione
558476-66-7P, 2-(4-Ethylphenyl)-5-[[2-(pyrrolidin-1-
yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558476-67-8P,
2-(4-Ethylphenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-
dione 558476-68-9P, 5-[[2-(Dimethylamino)ethyl]amino]-2-(2,6-
fluoro-6-methoxyphenyl)-1,3-benzothiazole-4,7-dione 558476-69-0P,
6-[[2-(Dimethylamino)ethyl]amino]-2-(2-fluoro-6-methoxyphenyl)-1,3-
benzoxazole-4,7-dione 558476-71-4P, 2-Cyclohexyl-5-[[2-
(dimethylamino)ethyl]amino]-1,3-benzothiazole-4,7-dione
558476-72-5P, 2-Cyclohexyl-6-[[2-(dimethylamino)ethyl]amino]-1,3-
benzothiazole-4,7-dione 819792-46-6P, 2-Cyclopropyl-5-[[2-
(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 819792-47-7P,
2-Cyclopropyl-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-
dione

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(Cdc25 inhibitors; prepn. and pharmaceutical compns. of
benzothiazolodiones, benzoxazolodiones, naphthoquinones, and related
compds. for use in chemotherapy)


17 558476-05-1 CAPLUS
18 4,7-Benzoxazolodione, 5-[[2-(dimethylamino)ethyl]amino]-2-phenyl- (9CI)
19 (CA INDEX NAME)

RN 558475-11-9 CAPLUS
CN 4,7-Benzoxazolidone, 2-{4-(diethylamino)phenyl}-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)


RN 550475-15-3 CAPLUS
 CN 4,7-Benzoxazolidione, 2-(4-chlorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-
 (9CI) (CA INDEX NAME)

10562949a


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-16-4 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-chlorophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-17-5 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-chlorophenyl)-5-[[3-(dimethylamino)propyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-18-6 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-chlorophenyl)-6-[[3-(dimethylamino)propyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-21-1 CAPLUS
CN 4,7-Benzoxazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 4,7-Benzoxazolidione, 2-(2-bromophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-26-6 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-bromophenyl)-6-[[3-(dimethylamino)propyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-27-7 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-bromophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-28-8 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-bromophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-29-9 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-bromophenyl)-5-[[3-(dimethylamino)propyl]amino]- (9CI) (CA INDEX NAME)

Karen Cheng


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-22-2 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 558475-23-3 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-fluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-24-4 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-fluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-25-5 CAPLUS


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-30-2 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-bromophenyl)-6-[[3-(dimethylamino)propyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-31-3 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-chlorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-32-4 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-chlorophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-33-5 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-chlorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

10562949a


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-34-6 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-chlorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-35-7 CAPLUS
CN 4,7-Benzoxazolidione, 2-(3-bromophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-36-8 CAPLUS
CN 4,7-Benzoxazolidione, 2-(3-bromophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-37-9 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-bromophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 558475-41-5 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-fluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-42-6 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-fluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-43-7 CAPLUS
CN 4,7-Benzoxazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-45-9 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-51-7 CAPLUS
CN 4,7-Benzoxazolidione, 5-[[3-(dimethylamino)propyl]amino]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Karen Cheng


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-38-0 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-bromophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-39-1 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-bromophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-40-4 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-bromophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 558475-53-9 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[3-(dimethylamino)propyl]amino]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-53-9 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[3-(dimethylamino)propyl]amino]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 558475-54-0 CAPLUS
CN 4,7-Benzoxazolidione, 2-(3,5-difluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-56-2 CAPLUS
CN 4,7-Benzoxazolidione, 2-(3,5-difluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-57-3 CAPLUS

10562949a


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 4,7-Benzoxazolidione, 2-(3,5-difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-59-5 CAPLUS
CN 4,7-Benzoxazolidione, 2-(3,5-difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-61-9 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2,5-difluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-63-1 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2,5-difluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-69-7 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2,3-difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-71-1 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2,3-difluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-72-2 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2,3-difluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-74-4 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2,3-difluorophenyl)-5-[[3-(dimethylamino)propyl]amino]- (9CI) (CA INDEX NAME)


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 558475-65-3 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2,5-difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-67-5 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2,5-difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-68-6 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2,3-difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-75-5 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2,3-difluorophenyl)-6-[[3-(dimethylamino)propyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-76-6 CAPLUS
CN 4,7-Benzoxazolidione, 5-[[2-(1-pyrrolidinyl)ethyl]amino]-2-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 558475-78-8 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-80-2 CAPLUS
CN 4,7-Benzoxazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)


Karen Cheng

10562949a


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 558475-81-3 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-82-4 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-83-5 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-90-4 CAPLUS
CN 4,7-Benzoxazolidione, 2-[2-fluoro-6-(trifluoromethyl)phenyl]-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-92-6 CAPLUS
CN 4,7-Benzoxazolidione, 2-[2-fluoro-6-(trifluoromethyl)phenyl]-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-93-7 CAPLUS
CN 4,7-Benzoxazolidione, 2-[2-fluoro-6-(trifluoromethyl)phenyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-95-9 CAPLUS
CN 4,7-Benzoxazolidione, 5-[[3-(dimethylamino)propyl]amino]-2-[2-fluoro-6-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 558475-85-7 CAPLUS
CN 4,7-Benzoxazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-86-8 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-88-0 CAPLUS
CN 4,7-Benzoxazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-[2-fluoro-6-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-97-1 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[3-(dimethylamino)propyl]amino]-2-[2-fluoro-6-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 558475-98-2 CAPLUS
CN 4,7-Benzoxazolidione, 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-99-3 CAPLUS
CN 4,7-Benzoxazolidione, 2-[2-chloro-5-(trifluoromethyl)phenyl]-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-00-9 CAPLUS
CN 4,7-Benzoxazolidione, 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)


Karen Cheng

10562949a


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 558476-01-0 CAPLUS
CN 4,7-Benzoxazolidione, 2-([2-(1-pyrrolidinyl)ethyl]amino)-6-([2-(2-chloro-5-(trifluoromethyl)phenyl)]-5-[[3-(dimethylamino)propyl]amino])-(9CI) (CA INDEX NAME)




RN 558476-02-1 CAPLUS
CN 4,7-Benzoxazolidione, 2-([2-(1-pyrrolidinyl)ethyl]amino)-6-([2-(2-chloro-5-(trifluoromethyl)phenyl)]-5-[[3-(dimethylamino)propyl]amino])-(9CI) (CA INDEX NAME)




RN 558476-03-2 CAPLUS
CN 4,7-Benzoxazolidione, 2-([2-(1-pyrrolidinyl)ethyl]amino)-6-([2-(2-chloro-5-(trifluoromethyl)phenyl)]-5-[[3-(dimethylamino)propyl]amino])-(9CI) (CA INDEX NAME)


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 4,7-Benzoxazolidione, 2-([2-(1-pyrrolidinyl)ethyl]amino)-6-([2-(2-chloro-5-(trifluoromethyl)phenyl)]-5-[[3-(dimethylamino)propyl]amino])-(9CI) (CA INDEX NAME)




RN 558476-08-7 CAPLUS
CN 4,7-Benzoxazolidione, 2-([2-(1-pyrrolidinyl)ethyl]amino)-6-([2-(2-chloro-5-(trifluoromethyl)phenyl)]-5-[[3-(dimethylamino)propyl]amino])-(9CI) (CA INDEX NAME)



RN 558476-09-8 CAPLUS
CN 4,7-Benzoxazolidione, 2-([2-(1-pyrrolidinyl)ethyl]amino)-6-([2-(2-chloro-5-(trifluoromethyl)phenyl)]-5-[[3-(dimethylamino)propyl]amino])-(9CI) (CA INDEX NAME)




RN 558476-12-3 CAPLUS
CN 4,7-Benzothiazolidione, 2-cyclohexyl-5-[[2-(1-pyrrolidinyl)ethyl]amino])-(9CI) (CA INDEX NAME)




Karen Cheng


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558476-04-3 CAPLUS
CN 4,7-Benzoxazolidione, 2-([2-(1-pyrrolidinyl)ethyl]amino)-6-([2-(2-chloro-5-(trifluoromethyl)phenyl)]-5-[[3-(dimethylamino)propyl]amino])-(9CI) (CA INDEX NAME)



RN 558476-05-4 CAPLUS
CN 4,7-Benzoxazolidione, 2-([2-(1-pyrrolidinyl)ethyl]amino)-6-([2-(2-chloro-5-(trifluoromethyl)phenyl)]-5-[[3-(dimethylamino)propyl]amino])-(9CI) (CA INDEX NAME)




RN 558476-06-5 CAPLUS
CN 4,7-Benzoxazolidione, 2-([2-(1-pyrrolidinyl)ethyl]amino)-6-([2-(2-chloro-5-(trifluoromethyl)phenyl)]-5-[[3-(dimethylamino)propyl]amino])-(9CI) (CA INDEX NAME)




RN 558476-07-6 CAPLUS

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 558476-13-4 CAPLUS
CN 4,7-Benzothiazolidione, 2-cyclohexyl-6-[[2-(1-pyrrolidinyl)ethyl]amino])-(9CI) (CA INDEX NAME)




RN 558476-22-5 CAPLUS
CN 4,7-Benzothiazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(2-methoxyphenyl)-(9CI) (CA INDEX NAME)



RN 558476-23-6 CAPLUS
CN 4,7-Benzothiazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(2-methoxyphenyl)-(9CI) (CA INDEX NAME)




RN 558476-24-7 CAPLUS
CN 4,7-Benzothiazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(2-fluorophenyl)-(9CI) (CA INDEX NAME)




RN 558476-25-8 CAPLUS
CN 4,7-Benzothiazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(2-fluorophenyl)-(9CI) (CA INDEX NAME)

10562949a


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
fluorophenyl)- (9CI) (CA INDEX NAME)




RN 558476-26-9 CAPLUS
CN 4,7-Benzothiazolodione, 2-(2-fluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-27-0 CAPLUS
CN 4,7-Benzothiazolodione, 2-(2-fluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-28-1 CAPLUS
CN 4,7-Benzothiazolodione, 2-(4-fluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558476-33-8 CAPLUS
CN 4,7-Benzothiazolodione, 2-(2,6-difluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558476-34-9 CAPLUS
CN 4,7-Benzothiazolodione, 2-(2,6-difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-35-0 CAPLUS
CN 4,7-Benzothiazolodione, 2-(2,6-difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-42-9 CAPLUS
CN 4,7-Benzothiazolodione, 2-(2,4-difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 558476-29-2 CAPLUS
CN 4,7-Benzothiazolodione, 2-(4-fluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558476-30-5 CAPLUS
CN 4,7-Benzothiazolodione, 5-[[2-(dimethylamino)ethyl]amino]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 558476-31-6 CAPLUS
CN 4,7-Benzothiazolodione, 6-[[2-(dimethylamino)ethyl]amino]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 558476-32-7 CAPLUS
CN 4,7-Benzothiazolodione, 2-(2,6-difluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558476-43-0 CAPLUS
CN 4,7-Benzoxazolodione, 2-(2,4-difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558476-44-1 CAPLUS
CN 4,7-Benzoxazolodione, 5-[[2-(dimethylamino)ethyl]amino]-2-(2,3,4-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 558476-45-2 CAPLUS
CN 4,7-Benzoxazolodione, 6-[[2-(dimethylamino)ethyl]amino]-2-(2,3,4-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 558476-46-3 CAPLUS
CN 4,7-Benzoxazolodione, 5-[[2-(1-pyrrolidinyl)ethyl]amino]-2-(2,3,4-trifluorophenyl)- (9CI) (CA INDEX NAME)


Karen Cheng

10562949a


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 558476-47-4 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-(2,3,4-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 558476-48-5 CAPLUS
CN 4,7-Benzoxazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(3-fluoro-4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 558476-49-6 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(3-fluoro-4-methylphenyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558476-53-2 CAPLUS
CN 4,7-Benzothiazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 558476-54-3 CAPLUS
CN 4,7-Benzothiazolidione, 2-(4-chlorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-55-4 CAPLUS
CN 4,7-Benzothiazolidione, 2-(4-chlorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-56-5 CAPLUS
CN 4,7-Benzothiazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 558476-50-9 CAPLUS
CN 4,7-Benzoxazolidione, 2-(3-fluoro-4-methylphenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-51-0 CAPLUS
CN 4,7-Benzoxazolidione, 2-(3-fluoro-4-methylphenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-52-1 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-chlorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558476-57-6 CAPLUS
CN 4,7-Benzothiazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)- (9CI) (CA INDEX NAME)



RN 558476-58-7 CAPLUS
CN 4,7-Benzothiazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 558476-59-8 CAPLUS
CN 4,7-Benzothiazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)




Karen Cheng


10562949a

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 558476-60-1 CAPLUS
CN 4,7-Benzothiazolodione, 5-[[2-(1-pyrrolidinyl)ethyl]amino]-2-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 558476-61-2 CAPLUS
CN 4,7-Benzothiazolodione, 6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 558476-64-5 CAPLUS
CN 4,7-Benzoxazolodione, 5-[[2-(dimethylamino)ethyl]amino]-2-(4-ethylphenyl)- (9CI) (CA INDEX NAME)




RN 558476-65-6 CAPLUS
CN 4,7-Benzoxazolodione, 6-[[2-(dimethylamino)ethyl]amino]-2-(4-ethylphenyl)- (9CI) (CA INDEX NAME)




L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558476-71-4 CAPLUS
CN 4,7-Benzothiazolodione, 2-cyclohexyl-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558476-72-5 CAPLUS
CN 4,7-Benzothiazolodione, 2-cyclohexyl-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 819792-46-6 CAPLUS
CN 4,7-Benzoxazolodione, 2-cyclopropyl-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 819792-47-7 CAPLUS
CN 4,7-Benzoxazolodione, 2-cyclopropyl-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)

Karen Cheng


L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558476-66-7 CAPLUS
CN 4,7-Benzoxazolodione, 2-(4-ethylphenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558476-67-8 CAPLUS
CN 4,7-Benzoxazolodione, 2-(4-ethylphenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-68-9 CAPLUS
CN 4,7-Benzoxazolodione, 5-[[2-(dimethylamino)ethyl]amino]-2-(2-fluoro-6-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 558476-69-0 CAPLUS
CN 4,7-Benzoxazolodione, 6-[[2-(dimethylamino)ethyl]amino]-2-(2-fluoro-6-

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 817553-20-1P, 2-(2-Chloro-6-fluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzothiazole-4,7-dione
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antitumor agent; preparation and pharmaceutical compns. of benzothiazolodiones, benzoxazolodiones, and analogs for use in chemotherapy)
RN 817553-20-1 CAPLUS
CN 4,7-Benzothiazolodione, 2-(2-chloro-6-fluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10562949a

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:609 CAPLUS

DOCUMENT NUMBER: 142:93810

TITLE:

5- or 6-substituted benzothiazole-4,7-diones and benzoxazole-4,7-diones, their preparation processes via amination, and their use as inhibitors of cdc25 and CD45 phosphatases

INVENTOR(S): Gálceri Contour, Marie Odile Lavergne, Olivier

PATENT ASSIGNEE(S): Société de Conseils de Recherches et d'Applications Scientifiques SCRAS, Fr.

SOURCE: Fr. Demande, 52 pp.

CODEN: FROXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2856686	A1	20041231	FR 2003-7648	20030625
AU 2004251912	A1	20050106	AU 2004-251912	20040624
CA 2530662	A1	20050106	CA 2004-2530662	20040624
WO 2005000843	A2	20050106	WO 2004-FR1578	20040624
WO 2005000843	A3	20050526		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BV, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, T, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HL, HR, NE, SN, TD, TG				
EP 1641789	A2	20060405	EP 2004-767434	20040624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004011871	A	20060808	BR 2004-11871	20040624
CN 1842522	A	20061004	CN 2004-80024394	20040624
NO 2006000124	A	20060120	NO 2006-124	20060109
US 2006135573	A1	20060622	US 2006-562949	20060210
PRIORITY APPL. INFO.:			FR 2003-7648	A 20030625
OTHER SOURCE(S):		MARPAT 142:93810	WO 2004-FR1578	V 20040624
GI				

current app.

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



AB The invention is directed to a process for the preparation of benzothiazole-4,7-diones and benzoxazole-4,7-diones monosubstituted in position 5 or 6 by an (un)substituted amino group (I) by amination of their 5- or 6-methoxy derivs. with amines of formula NHRR2 in a protic solvent [W = S, O; R1 = H, alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, etc.; R2 = H, alkyl, aralkyl; or R1NR2 = (un)substituted 4-8-membered heterocyclyl; R4 = cyclocyclo/cycloalkyl, CN, NH2, (un)substituted heterocyclyl, etc.]. The invention is also directed to the use of compds. I and their pharmaceutically acceptable salts which are inhibitors of both cdc25 phosphatases (in particular cdc25-C) and the phosphatase CD45. According to the invention, compds. I can be used in particular to prepare a drug intended to treat cancer. For instance, invention compound II was prepared via amination of 2-(2,6-difluorophenyl)-5-methoxy-1,3-benzothiazole-4,7-dione (preparation given) with N,N-dimethylethylenediamine in anhydrous EtOH at 70° for 2 h. I inhibited the phosphatase activity of purified recombinant cdc25-C in vitro with IC50 values of $\leq 10 \mu\text{M}$. I had IC50 values of $\leq 10 \mu\text{M}$ against proliferation of human cancer cell lines Mia-Paca2 and DU-145 in vitro.

IT 558476-28-1P, 2-(4-Fluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-30-5P, 5-[[2-(Dimethylamino)ethyl]amino]-2-(4-fluorophenyl)-1,3-benzothiazole-4,7-dione 558476-34-9P, 2-(2,6-Difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzothiazole-4,7-dione 817553-15-4P, 2-(2-Chloro-6-fluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzothiazole-4,7-dione 817553-20-1P, 2-(2-Chloro-6-fluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzothiazole-4,7-dione

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN


L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amine product, antiproliferative agent; process for the prepn. of monoamino benzothiazole-4,7-diones and benzoxazole-4,7-diones as inhibitors of cdc25 and CD45 phosphatases by amination of methoxy derivs.)


RN 558476-28-1 CAPLUS

CN 4,7-Benzothiazole-4,7-dione, 2-(4-fluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-30-5 CAPLUS

CN 4,7-Benzothiazole-4,7-dione, 5-[[2-(dimethylamino)ethyl]amino]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 558476-34-9 CAPLUS


CN 4,7-Benzothiazole-4,7-dione, 2-(2,6-difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 817553-15-4 CAPLUS


CN 4,7-Benzothiazole-4,7-dione, 2-(2-chloro-6-fluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 817553-20-1 CAPLUS

CN 4,7-Benzothiazole-4,7-dione, 2-(2-chloro-6-fluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Karen Cheng

10562949a

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2003:532654 CAPLUS

DOCUMENT NUMBER: 139:101120

TITLE: Benzothiazole-4,7-dione and benzoxazole-4,7-dione derivatives, their preparation, and their use as inhibitors of cdc25 and CD45 phosphatases

INVENTOR(S): Galcera Contour, Marie-Odile; Lavegner, Olivier; Brezak, Pannetier, Marie-Christine; Prevost, Gregoire

PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.

SOURCE: PCT Int. Appl., 151 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055868	A1	20030710	WO 2002-FR4544	20021224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MT, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2834289	A1	20030704	FR 2001-16889	20011227
FR 2834289	B1	20040319		
CA 2471113	A1	20030710	CA 2002-2471113	20021224
AU 2002364485	A1	20030715	AU 2002-364485	20021224
EP 1461326	A1	20040929	EP 2002-799849	20021224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015336	A	20041116	BR 2002-15336	20021224
JP 2005517676	T	20050616	JP 2003-556399	20021224
NZ 533454	A2	20060224	NZ 2002-533454	20021224
HU 200600238	A2	20060628	HU 2006-238	20021224
IN 2004DN01689	A	20070112	IN 2004-DN1689	20040415
US 2006040996	A1	20060223	US 2004-500411	20040624
NO 2004003173	A	20040726	NO 2004-3173	20040726
PRIORITY APPL. INFO.:			FR 2001-16889	A 20011227
			FR 2002-9415	A 20020725
			WO 2002-FR4544	W 20021224

OTHER SOURCE(S): MARPAT 139:101120

G1

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



AB The invention discloses the use of new compds, which are inhibitors of both cdc25 phosphatases (in particular cdc25-C) and the phosphatase CD45. The disclosed compds. are the heterocyclic diones I and their pharmaceutically acceptable salts [wherein: R1 = H, alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, (CH2)-X-Y or (CH2)-2-NR5R6, indanyl, tetralinyl, (un)substituted saturated N/O/S heterocyclyl bound at C; also (when W = O) R1 = (un)substituted aryl; R2 = H, alkyl, aralkyl, or NR1R2 may form a heterocyclic ring; R3 = H, halo, alkyl, haloalkyl, alkoxy, alkylthio; R4 = alkyl, cycloalkyl, cycloalkylalkyl, cyano, amino, CH2CO2H or alkyl esters, CH2CONH2 or CH2NH2 or deriv., (un)substituted aryl or heteroaryl; R5, R6 = H, alkyl, aralkyl, or (CH2)nOH in which n = 1-6; or R5 = alkoxy carbonyl, haloalkoxy carbonyl, or aralkoxy carbonyl, and R6 = H or Me; or NR5R6 = saturated, (un)substituted N-heterocycle; X, Z =

alkylene; Y = saturated, (un)substituted mono-, di-, or tricyclic carbo- or N/O/S heterocycle, or (un)substituted carbo- or heterocyclic aryl; and W = O or S.]. According to the invention, compds. I can be used in particular to prepare a drug intended to treat cancer. Claimed uses include treatment of tumors, non-malignant proliferative disorders, neurodegenerative disorders, parasitic or viral infections, alopecia of several origins, autoimmune disorders, graft rejection, and inflammatory or allergic disorders. Nearly 200 examples are prepared and individually cited in claims. Some compds. were prepared as pairs of regioisomers, or as unidentified members of such pairs. For instance, invention compound II was prepared in 6 steps. Thus, 2-methyl-5-methoxy-1,3-benzoxazole was n-brominated with NBS, and the bromide anion was removed with morpholine. The product was nitrated in the 4-position, and the nitro group was reduced to amino with SnCl2. The 4-amino was oxidized with Fremy's salt to give the 4,7-dione, which was condensed at the 5-methoxy group with 2-(dimethylamino)ethylamine to give II. Most compds. I inhibited the phosphatase activity of purified recombinant cdc25-C in vitro with IC50 values of $\leq 10 \mu\text{M}$. Five compds. inhibited the tyrosine phosphatase activity of CD45 at $\leq 10 \mu\text{M}$. Most compds., including II, had IC50 values of $\leq 10 \mu\text{M}$ against proliferation of human cancer cell lines Mia-Paca2 and DU-145 in vitro.

IT 558475-05-1P, 5-[[2-(Dimethylamino)ethyl]amino]-2-phenyl-1,3-benzoxazole-4,7-dione 558475-06-2P, 6-[[2-(Dimethylamino)ethyl]amino]-2-phenyl-1,3-benzoxazole-4,7-dione 558475-09-5P, 2-(2,6-Difluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-10-8P, 2-(2,6-Difluorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-11-9P, 2-[4-(Diethylamino)phenyl]-5-[[2-

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

(dimethylamino)-1-yl]ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-12-0P, 2-[4-(Diethylamino)phenyl]-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-13-1P, 2-[4-(Diethylamino)phenyl]-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-14-2P, 2-[4-(Diethylamino)phenyl]-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-15-3P, 2-(4-Chlorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-16-4P, 2-(4-Chlorophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-17-5P, 2-(4-Chlorophenyl)-5-[[2-(dimethylamino)propyl]amino]-1,3-benzoxazole-4,7-dione 558475-18-6P, 2-(4-Chlorophenyl)-6-[[2-(dimethylamino)propyl]amino]-1,3-benzoxazole-4,7-dione 558475-19-7P, 2-(2-Fluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-20-8P, 2-(2-Fluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-21-1P, 2-(2-Fluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-22-2P, 2-(2-Fluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-23-3P, 2-(2-Fluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-24-4P, 2-(2-Fluorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-25-5P, 2-(2-Bromophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-26-6P, 2-(2-Bromophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-27-7P, 2-(2-Bromophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-28-8P, 2-(2-Bromophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-29-9P, 2-(2-Bromophenyl)-5-[[2-(dimethylamino)propyl]amino]-1,3-benzoxazole-4,7-dione 558475-30-2P, 2-(2-Bromophenyl)-6-[[2-(dimethylamino)propyl]amino]-1,3-benzoxazole-4,7-dione 558475-31-3P, 2-(2-Chlorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-32-4P, 2-(2-Chlorophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-33-5P, 2-(2-Chlorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-34-6P, 2-(2-Chlorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-35-7P, 2-(3-Bromophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-36-8P, 2-(3-Bromophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-37-9P, 2-(4-Bromophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-38-0P, 2-(4-Bromophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-39-1P, 2-(4-Bromophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-40-2P, 2-(4-Bromophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-41-3P, 2-(4-Fluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-42-4P, 2-(4-Fluorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-43-5P, 5-[[2-(Dimethylamino)ethyl]amino]-2-(4-fluorophenyl)-1,3-benzoxazole-4,7-dione 558475-45-9P, 6-[[2-(Dimethylamino)ethyl]amino]-2-(4-fluorophenyl)-1,3-benzoxazole-4,7-dione 558475-46-0P, 5-[[3-(Dimethylamino)propyl]amino]-2-(4-fluorophenyl)-1,3-benzoxazole-4,7-dione 558475-47-1P, 6-[[3-(Dimethylamino)propyl]amino]-2-(4-fluorophenyl)-1,3-benzoxazole-4,7-dione 558475-48-2P, 2-(3,5-Difluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-49-3P, 2-(3,5-Difluorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-50-4P, 2-(3,5-Difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-51-5P, 2-(3,5-Difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-52-6P, 2-(3,5-Difluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-53-7P, 2-(3,5-Difluorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-54-8P, 2-(3,5-Difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-55-9P, 2-(3,5-Difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-56-0P, 2-(3,5-Difluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-57-1P, 2-(3,5-Difluorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-58-2P, 2-(3,5-Difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-59-3P, 2-(3,5-Difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-60-4P, 2-(2,5-Difluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-61-5P, 2-(2,5-Difluorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-62-6P, 2-(2,5-Difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-63-7P, 2-(2,5-Difluorophenyl)-6-[[2-

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)


(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-64-8P, 2-(2,5-Difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-65-9P, 2-(2,5-Difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-66-0P, 2-(2,5-Difluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-67-1P, 2-(2,5-Difluorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-68-2P, 2-(2,5-Difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-69-3P, 2-(2,5-Difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-70-4P, 2-(2,5-Difluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-71-5P, 2-(2,5-Difluorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-72-6P, 2-(2,5-Difluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-73-7P, 2-(2,5-Difluorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-74-8P, 2-(2,5-Difluorophenyl)-5-[[2-(dimethylamino)propyl]amino]-1,3-benzoxazole-4,7-dione 558475-75-9P, 2-(2,5-Difluorophenyl)-6-[[2-(dimethylamino)propyl]amino]-1,3-benzoxazole-4,7-dione 558475-76-0P, 5-[[2-(Pyrrolidin-1-yl)ethyl]amino]-2-(3,4,5-trifluorophenyl)-1,3-benzoxazole-4,7-dione 558475-77-1P, 6-[[2-(Pyrrolidin-1-yl)ethyl]amino]-2-(3,4,5-trifluorophenyl)-1,3-benzoxazole-4,7-dione 558475-78-2P, 6-[[2-(Pyrrolidin-1-yl)ethyl]amino]-2-(3,4,5-trifluorophenyl)-1,3-benzoxazole-4,7-dione 558475-79-3P, 5-[[2-(Dimethylamino)ethyl]amino]-2-(3,4,5-trifluorophenyl)-1,3-benzoxazole-4,7-dione 558475-80-4P, 5-[[2-(Dimethylamino)ethyl]amino]-2-(3,4,5-trifluorophenyl)-1,3-benzoxazole-4,7-dione 558475-81-5P, 6-[[2-(Dimethylamino)ethyl]amino]-2-(3,4,5-trifluorophenyl)-1,3-benzoxazole-4,7-dione 558475-82-6P, 5-[[2-(Pyrrolidin-1-yl)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)-1,3-benzoxazole-4,7-dione 558475-83-7P, 6-[[2-(Pyrrolidin-1-yl)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)-1,3-benzoxazole-4,7-dione 558475-84-8P, 5-[[2-(Dimethylamino)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)-1,3-benzoxazole-4,7-dione 558475-85-9P, 6-[[2-(Dimethylamino)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)-1,3-benzoxazole-4,7-dione 558475-86-0P, 6-[[2-(Dimethylamino)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)-1,3-benzoxazole-4,7-dione 558475-87-1P, 5-[[2-(Dimethylamino)ethyl]amino]-2-(2-fluoro-6-(trifluoromethyl)phenyl)-1,3-benzoxazole-4,7-dione 558475-88-2P, 6-[[2-(Dimethylamino)ethyl]amino]-2-(2-fluoro-6-(trifluoromethyl)phenyl)-1,3-benzoxazole-4,7-dione 558475-89-3P, 6-[[2-(Dimethylamino)ethyl]amino]-2-(2-fluoro-6-(trifluoromethyl)phenyl)-1,3-benzoxazole-4,7-dione 558475-90-4P, 6-[[2-(Dimethylamino)ethyl]amino]-2-(2-fluoro-6-(trifluoromethyl)phenyl)-1,3-benzoxazole-4,7-dione 558475-91-5P, 6-[[2-(Dimethylamino)ethyl]amino]-2-(2-fluoro-6-(trifluoromethyl)phenyl)-1,3-benzoxazole-4,7-dione 558475-92-6P, 2-(2-Fluoro-6-(trifluoromethyl)phenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-93-7P, 2-(2-Fluoro-6-(trifluoromethyl)phenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-94-8P, 5-[[3-(Dimethylamino)propyl]amino]-2-(2-fluoro-6-(trifluoromethyl)phenyl)-1,3-benzoxazole-4,7-dione 558475-95-9P, 6-[[3-(Dimethylamino)propyl]amino]-2-(2-fluoro-6-(trifluoromethyl)phenyl)-1,3-benzoxazole-4,7-dione 558475-96-0P, 6-[[3-(Dimethylamino)propyl]amino]-2-(2-fluoro-6-(trifluoromethyl)phenyl)-1,3-benzoxazole-4,7-dione 558475-97-1P, 6-[[3-(Dimethylamino)propyl]amino]-2-(2-fluoro-6-(trifluoromethyl)phenyl)-1,3-benzoxazole-4,7-dione 558475-98-2P, 2-(2-Chloro-5-(trifluoromethyl)phenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558475-99-3P, 2-(2-Chloro-5-(trifluoromethyl)phenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558476-00-4P, 2-(2-Chloro-5-(trifluoromethyl)phenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558476-01-5P, 2-(2-Chloro-5-(trifluoromethyl)phenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558476-02-6P, 2-(2-Chloro-5-(trifluoromethyl)phenyl)-5-[[3-(dimethylamino)propyl]amino]-1,3-benzoxazole-4,7-dione 558476-03-7P, 2-(2-Chloro-5-(trifluoromethyl)phenyl)-6-[[3-(dimethylamino)propyl]amino]-1,3-benzoxazole-4,7-dione 558476-04-8P, 2-(2-Chloro-6-fluorophenyl)-5-[[3-(dimethylamino)propyl]amino]-1,3-benzoxazole-4,7-dione 558476-05-9P, 2-(2-Chloro-6-fluorophenyl)-6-[[3-(dimethylamino)propyl]amino]-1,3-benzoxazole-4,7-dione 558476-06-0P, 2-(2-Chloro-6-fluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558476-07-1P, 2-(2-Chloro-6-fluorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558476-08-2P, 2-(3,4-Dimethoxyphenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione

Karen Cheng


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

558476-09-8P, 2-[[2-(4-Dimethoxyphenyl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558476-12-3P, 2-Cyclohexyl-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-13-4P, 2-Cyclohexyl-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-22-6P, 5-[[2-(Dimethylamino)ethyl]amino]-2-(2-methoxyphenyl)-1,3-benzothiazole-4,7-dione 558476-23-6P, 6-[[2-(Dimethylamino)ethyl]amino]-2-(2-methoxyphenyl)-1,3-benzothiazole-4,7-dione 558476-24-7P, 5-[[2-(Dimethylamino)ethyl]amino]-2-(2-fluorophenyl)-1,3-benzothiazole-4,7-dione 558476-25-8P, 6-[[2-(Dimethylamino)ethyl]amino]-2-(2-fluorophenyl)-1,3-benzothiazole-4,7-dione 558476-26-9P, 2-(2-Fluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-27-0P, 2-(2-Fluorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-28-1P, 2-(4-Fluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-29-2P, 2-(4-Fluorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-30-5P, 5-[[2-(Dimethylamino)ethyl]amino]-2-(4-fluorophenyl)-1,3-benzothiazole-4,7-dione 558476-31-6P, 6-[[2-(Dimethylamino)ethyl]amino]-2-(4-fluorophenyl)-1,3-benzothiazole-4,7-dione 558476-32-7P, 2-(2,6-Difluorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-33-8P, 2-(2,6-Difluorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-34-9P, 2-(2,6-Difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-35-0P, 2-(2,6-Difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-42-9P, 2-(2,4-Difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558476-43-0P, 2-(2,4-Difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558476-44-1P, 5-[[2-(Dimethylamino)ethyl]amino]-2-(2,3,4-trifluorophenyl)-1,3-benzoxazole-4,7-dione 558476-45-2P, 6-[[2-(Dimethylamino)ethyl]amino]-2-(2,3,4-trifluorophenyl)-1,3-benzoxazole-4,7-dione 558476-46-3P, 5-[[2-(Pyrrolidin-1-yl)ethyl]amino]-2-(2,3,4-trifluorophenyl)-1,3-benzoxazole-4,7-dione 558476-47-4P, 6-[[2-(Pyrrolidin-1-yl)ethyl]amino]-2-(2,3,4-trifluorophenyl)-1,3-benzoxazole-4,7-dione 558476-48-5P, 2-(3-Fluoro-4-methylphenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558476-49-6P, 2-(3-Fluoro-4-methylphenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzoxazole-4,7-dione 558476-50-9P, 2-(3-Fluoro-4-methylphenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558476-51-0P, 2-(3-Fluoro-4-methylphenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558476-52-1P, 2-(4-Chlorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-53-2P, 2-(4-Chlorophenyl)-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-54-3P, 2-(4-Chlorophenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-55-4P, 2-(4-Chlorophenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-56-5P, 5-[[2-(Dimethylamino)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)-1,3-benzothiazole-4,7-dione 558476-57-6P, 6-[[2-(Dimethylamino)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)-1,3-benzothiazole-4,7-dione 558476-58-7P, 5-[[2-(Dimethylamino)ethyl]amino]-2-(3,4,5-trifluorophenyl)-1,3-benzothiazole-


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-10-9 CAPLUS
CN 4,7-Benzoxazolidione, 2-[(2,6-difluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-11-9 CAPLUS
CN 4,7-Benzoxazolidione, 2-[(4-(diethylamino)phenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-12-0 CAPLUS
CN 4,7-Benzoxazolidione, 2-[(4-(diethylamino)phenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-13-1 CAPLUS
CN 4,7-Benzoxazolidione, 2-[(4-(diethylamino)phenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

4,7-dione 558476-59-8P, 6-[[2-(Dimethylamino)ethyl]amino]-2-(3,4,5-trifluorophenyl)-1,3-benzothiazole-4,7-dione 558476-60-1P, 5-[[2-(Pyrrolidin-1-yl)ethyl]amino]-2-(2,4,6-trifluorophenyl)-1,3-benzothiazole-4,7-dione 558476-61-2P, 6-[[2-(Pyrrolidin-1-yl)ethyl]amino]-2-(2,4,6-trifluorophenyl)-1,3-benzothiazole-4,7-dione 558476-64-5P, 5-[[2-(Dimethylamino)ethyl]amino]-2-(4-ethylphenyl)-1,3-benzoxazole-4,7-dione 558476-65-6P, 6-[[2-(Dimethylamino)ethyl]amino]-2-(4-ethylphenyl)-1,3-benzoxazole-4,7-dione 558476-66-7P, 2-(4-Ethylphenyl)-5-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558476-67-8P, 2-(4-Ethylphenyl)-6-[[2-(pyrrolidin-1-yl)ethyl]amino]-1,3-benzoxazole-4,7-dione 558476-68-9P, 5-[[2-(Dimethylamino)ethyl]amino]-2-(2-fluoro-6-methoxyphenyl)-1,3-benzoxazole-4,7-dione 558476-69-0P, 6-[[2-(Dimethylamino)ethyl]amino]-2-(2-fluoro-6-methoxyphenyl)-1,3-benzoxazole-4,7-dione 558476-71-4P, 2-Cyclohexyl-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzothiazole-4,7-dione 558476-72-5P, 2-Cyclohexyl-6-[[2-(dimethylamino)ethyl]amino]-1,3-benzothiazole-4,7-dione
RU PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of benzothiazolidone and benzoxazolidone derivs. as inhibitors of cdc25 and CD45 phosphatases)
RN 558475-05-1 CAPLUS
CN 4,7-Benzoxazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-phenyl- (9CI) (CA INDEX NAME)




RN 558475-06-2 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-phenyl- (9CI) (CA INDEX NAME)




RN 558475-09-5 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2,6-difluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-14-2 CAPLUS
CN 4,7-Benzoxazolidione, 2-[(4-(diethylamino)phenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-15-3 CAPLUS
CN 4,7-Benzoxazolidione, 2-[(4-chlorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-16-4 CAPLUS
CN 4,7-Benzoxazolidione, 2-[(4-chlorophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-17-5 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-chlorophenyl)-5-[[3-(dimethylamino)propyl]amino]- (9CI) (CA INDEX NAME)

10562949a


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-18-6 CAPLUS
CN 4,7-Benzoxazolidione, 2-((4-chlorophenyl)-6-((3-(dimethylamino)propyl)amino)- (9CI) (CA INDEX NAME)



RN 558475-21-1 CAPLUS
CN 4,7-Benzoxazolidione, 5-([2-(dimethylamino)ethyl]amino)-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-22-2 CAPLUS
CN 4,7-Benzoxazolidione, 6-([2-(dimethylamino)ethyl]amino)-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-23-3 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-fluorophenyl)-5-([2-(1-pyrrolidinyl)ethyl]amino)- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 4,7-Benzoxazolidione, 2-(2-bromophenyl)-5-([2-(1-pyrrolidinyl)ethyl]amino)- (9CI) (CA INDEX NAME)




RN 558475-28-8 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-bromophenyl)-6-([2-(1-pyrrolidinyl)ethyl]amino)- (9CI) (CA INDEX NAME)



RN 558475-29-9 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-bromophenyl)-5-([3-(dimethylamino)propyl]amino)- (9CI) (CA INDEX NAME)




RN 558475-30-2 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-bromophenyl)-6-([3-(dimethylamino)propyl]amino)- (9CI) (CA INDEX NAME)




RN 558475-31-3 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-chlorophenyl)-5-([2-(dimethylamino)ethyl]amino)- (9CI) (CA INDEX NAME)

Karen Cheng


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-24-4 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-fluorophenyl)-6-([2-(1-pyrrolidinyl)ethyl]amino)- (9CI) (CA INDEX NAME)



RN 558475-25-5 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-bromophenyl)-5-([2-(dimethylamino)ethyl]amino)- (9CI) (CA INDEX NAME)




RN 558475-26-6 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-bromophenyl)-6-([2-(dimethylamino)ethyl]amino)- (9CI) (CA INDEX NAME)




RN 558475-27-7 CAPLUS


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-32-4 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-chlorophenyl)-6-([2-(dimethylamino)ethyl]amino)- (9CI) (CA INDEX NAME)



RN 558475-33-5 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-chlorophenyl)-5-([2-(1-pyrrolidinyl)ethyl]amino)- (9CI) (CA INDEX NAME)




RN 558475-34-6 CAPLUS
CN 4,7-Benzoxazolidione, 2-(2-chlorophenyl)-6-([2-(1-pyrrolidinyl)ethyl]amino)- (9CI) (CA INDEX NAME)




RN 558475-35-7 CAPLUS
CN 4,7-Benzoxazolidione, 2-(3-bromophenyl)-5-([2-(dimethylamino)ethyl]amino)- (9CI) (CA INDEX NAME)

10562949a


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-30-8 CAPLUS
CN 4,7-Benzoxazolidione, 2-(3-bromophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-37-9 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-bromophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-38-0 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-bromophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-39-1 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-bromophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 4,7-Benzoxazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-45-9 CAPLUS
CN 4,7-Benzoxazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 558475-51-7 CAPLUS
CN 4,7-Benzoxazolidione, 5-[[3-(dimethylamino)propyl]amino]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-53-9 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[3-(dimethylamino)propyl]amino]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-54-0 CAPLUS
CN 4,7-Benzoxazolidione, 2-(3,5-difluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

Karen Cheng


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-40-4 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-bromophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-41-5 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-fluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-42-6 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-fluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-43-7 CAPLUS


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-56-2 CAPLUS
CN 4,7-Benzoxazolidione, 2-(3,5-difluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-57-3 CAPLUS
CN 4,7-Benzoxazolidione, 2-(3,5-difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-59-5 CAPLUS
CN 4,7-Benzoxazolidione, 2-(3,5-difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




10562949a

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 558475-61-9 CAPLUS
 CN 4,7-Benzoxazolidione, 2-(2,5-difluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-63-1 CAPLUS
 CN 4,7-Benzoxazolidione, 2-(2,5-difluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-65-3 CAPLUS
 CN 4,7-Benzoxazolidione, 2-(2,5-difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-67-5 CAPLUS
 CN 4,7-Benzoxazolidione, 2-(2,3-difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 4,7-Benzoxazolidione, 2-(2,3-difluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-74-4 CAPLUS
 CN 4,7-Benzoxazolidione, 2-(2,3-difluorophenyl)-5-[[3-(dimethylamino)propyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-75-5 CAPLUS
 CN 4,7-Benzoxazolidione, 2-(2,3-difluorophenyl)-6-[[3-(dimethylamino)propyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-76-6 CAPLUS
 CN 4,7-Benzoxazolidione, 5-[[2-(1-pyrrolidinyl)ethyl]amino]-2-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-78-8 CAPLUS
 CN 4,7-Benzoxazolidione, 6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-(3,4,5-


Karen Cheng

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 558475-68-6 CAPLUS
 CN 4,7-Benzoxazolidione, 2-(2,3-difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-69-7 CAPLUS
 CN 4,7-Benzoxazolidione, 2-(2,3-difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-71-1 CAPLUS
 CN 4,7-Benzoxazolidione, 2-(2,3-difluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-72-2 CAPLUS


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 4,7-Benzoxazolidione, 2-(2,3-difluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558475-80-2 CAPLUS
 CN 4,7-Benzoxazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-81-3 CAPLUS
 CN 4,7-Benzoxazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-82-4 CAPLUS
 CN 4,7-Benzoxazolidione, 5-[[2-(1-pyrrolidinyl)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)- (9CI) (CA INDEX NAME)

10562949a


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 558475-83-5 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-85-7 CAPLUS
CN 4,7-Benzoxazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)- (9CI) (CA INDEX NAME)




RN 558475-86-8 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 4,7-Benzoxazolidione, 2-[[2-fluoro-6-(trifluoromethyl)phenyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-95-9 CAPLUS
CN 4,7-Benzoxazolidione, 5-[[3-(dimethylamino)propyl]amino]-2-[2-fluoro-6-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 558475-97-1 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[3-(dimethylamino)propyl]amino]-2-[2-fluoro-6-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 558475-98-2 CAPLUS
CN 4,7-Benzoxazolidione, 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-99-3 CAPLUS
CN 4,7-Benzoxazolidione, 2-[2-chloro-5-(trifluoromethyl)phenyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

Karen Cheng


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558475-88-0 CAPLUS
CN 4,7-Benzoxazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-[2-fluoro-6-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 558475-90-4 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-[2-fluoro-6-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 558475-92-6 CAPLUS
CN 4,7-Benzoxazolidione, 2-[2-fluoro-6-(trifluoromethyl)phenyl]-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558475-93-7 CAPLUS


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 4,7-Benzoxazolidione, 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558476-00-9 CAPLUS
CN 4,7-Benzoxazolidione, 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-01-0 CAPLUS
CN 4,7-Benzoxazolidione, 2-[2-chloro-5-(trifluoromethyl)phenyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-02-1 CAPLUS
CN 4,7-Benzoxazolidione, 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-[[3-(dimethylamino)propyl]amino]- (9CI) (CA INDEX NAME)

10562949a


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558476-03-2 CAPLUS
CN 4,7-Benzoxazolidione, 2-[(2-chloro-5-(trifluoromethyl)phenyl)-6-[[3-(dimethylamino)propyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-04-3 CAPLUS
CN 4,7-Benzoxazolidione, 2-[(2-chloro-6-fluorophenyl)-5-[[3-(dimethylamino)propyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-05-4 CAPLUS
CN 4,7-Benzoxazolidione, 2-[(2-chloro-6-fluorophenyl)-6-[[3-(dimethylamino)propyl]amino]- (9CI) (CA INDEX NAME)




L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558476-12-3 CAPLUS
CN 4,7-Benzothiazolidione, 2-cyclohexyl-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558476-13-4 CAPLUS
CN 4,7-Benzothiazolidione, 2-cyclohexyl-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558476-22-5 CAPLUS
CN 4,7-Benzothiazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 558476-23-6 CAPLUS
CN 4,7-Benzothiazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)


Karen Cheng

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 558476-06-5 CAPLUS
CN 4,7-Benzoxazolidione, 2-[(2-chloro-6-fluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558476-07-6 CAPLUS
CN 4,7-Benzoxazolidione, 2-[(2-chloro-6-fluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-08-7 CAPLUS
CN 4,7-Benzoxazolidione, 2-[(3,4-dimethoxyphenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-09-8 CAPLUS
CN 4,7-Benzoxazolidione, 2-[(3,4-dimethoxyphenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558476-24-7 CAPLUS
CN 4,7-Benzothiazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 558476-25-8 CAPLUS
CN 4,7-Benzothiazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 558476-26-9 CAPLUS
CN 4,7-Benzothiazolidione, 2-(2-fluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-27-0 CAPLUS
CN 4,7-Benzothiazolidione, 2-(2-fluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

10562949a


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558476-28-1 CAPLUS
CN 4,7-Benzothiazolidione, 2-((4-fluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558476-29-2 CAPLUS
CN 4,7-Benzothiazolidione, 2-((4-fluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-30-5 CAPLUS
CN 4,7-Benzothiazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 558476-31-6 CAPLUS
CN 4,7-Benzothiazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 4,7-Benzothiazolidione, 2-((2,6-difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-42-9 CAPLUS
CN 4,7-Benzothiazolidione, 2-((2,6-difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558476-43-0 CAPLUS
CN 4,7-Benzothiazolidione, 2-((2,4-difluorophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-44-1 CAPLUS
CN 4,7-Benzothiazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(2,3,4-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 558476-45-2 CAPLUS
CN 4,7-Benzothiazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(2,3,4-trifluorophenyl)- (9CI) (CA INDEX NAME)

Karen Cheng


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558476-32-7 CAPLUS
CN 4,7-Benzothiazolidione, 2-((2,6-difluorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558476-33-8 CAPLUS
CN 4,7-Benzothiazolidione, 2-((2,6-difluorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-34-9 CAPLUS
CN 4,7-Benzothiazolidione, 2-((2,6-difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-35-0 CAPLUS


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 4,7-Benzothiazolidione, 2-((2,6-difluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558476-46-3 CAPLUS
CN 4,7-Benzothiazolidione, 5-[[2-(1-pyrrolidinyl)ethyl]amino]-2-(2,3,4-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 558476-47-4 CAPLUS
CN 4,7-Benzothiazolidione, 6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-(2,3,4-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 558476-48-5 CAPLUS
CN 4,7-Benzothiazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(3-fluoro-4-methylphenyl)- (9CI) (CA INDEX NAME)

10562949a


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 558476-49-6 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(3-fluoro-4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 558476-50-9 CAPLUS
CN 4,7-Benzoxazolidione, 2-(3-fluoro-4-methylphenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-51-0 CAPLUS
CN 4,7-Benzoxazolidione, 2-(3-fluoro-4-methylphenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 558476-55-4 CAPLUS
CN 4,7-Benzothiazolidione, 2-(4-chlorophenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 558476-56-5 CAPLUS
CN 4,7-Benzothiazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)- (9CI) (CA INDEX NAME)




RN 558476-57-6 CAPLUS
CN 4,7-Benzothiazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(2,3,4,5-tetrafluorophenyl)- (9CI) (CA INDEX NAME)




RN 558476-58-7 CAPLUS
CN 4,7-Benzothiazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558476-52-1 CAPLUS
CN 4,7-Benzothiazolidione, 2-(4-chlorophenyl)-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-53-2 CAPLUS
CN 4,7-Benzothiazolidione, 2-(4-chlorophenyl)-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-54-3 CAPLUS
CN 4,7-Benzothiazolidione, 2-(4-chlorophenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558476-59-8 CAPLUS
CN 4,7-Benzothiazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 558476-60-1 CAPLUS
CN 4,7-Benzothiazolidione, 5-[[2-(1-pyrrolidinyl)ethyl]amino]-2-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 558476-61-2 CAPLUS
CN 4,7-Benzothiazolidione, 6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 558476-64-5 CAPLUS
CN 4,7-Benzoxazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(4-ethylphenyl)- (9CI) (CA INDEX NAME)


Karen Cheng

10562949a


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 558476-65-6 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(4-ethylphenyl)- (9CI) (CA INDEX NAME)



RN 558476-66-7 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-ethylphenyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-67-8 CAPLUS
CN 4,7-Benzoxazolidione, 2-(4-ethylphenyl)-6-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 558476-68-9 CAPLUS


L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 4,7-Benzoxazolidione, 5-[[2-(dimethylamino)ethyl]amino]-2-(2-fluoro-6-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 558476-69-0 CAPLUS
CN 4,7-Benzoxazolidione, 6-[[2-(dimethylamino)ethyl]amino]-2-(2-fluoro-6-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 558476-71-4 CAPLUS
CN 4,7-Benzothiazolidione, 2-cyclohexyl-5-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)





RN 558476-72-5 CAPLUS
CN 4,7-Benzothiazolidione, 2-cyclohexyl-6-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Karen Cheng

10562949b



chain nodes :
7 8 13 14 15 21 22 23 24 25 26
ring nodes :
1 2 3 4 5 6 9 10 11
ring/chain nodes :
16
chain bonds :
1-7 4-8 10-21 13-14 14-15 15-16 21-22 22-23 23-24 24-25 25-26
ring bonds :
1-6 1-2 2-3 2-9 3-4 3-11 4-5 5-6 9-10 10-11
exact/norm bonds :
1-6 1-2 1-7 2-3 2-9 3-4 3-11 4-5 4-8 5-6 9-10 10-11 10-21 13-14 14-15
15-16 21-22 22-23 23-24 24-25 25-26
isolated ring systems :
containing 1 :

G1:O,S


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 19:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS 25:CLASS 26:CLASS

L7 STRUCTURE UPLOADED

=> d
L7 HAS NO ANSWERS
L7 STR

Karen Cheng

10562949b



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 08:27:36 ON 27 MAR 2007)

FILE 'REGISTRY' ENTERED AT 08:27:44 ON 27 MAR 2007

L1 STRUCTURE UPLOADED

L2 211 S L1 FULL

FILE 'CAPLUS' ENTERED AT 08:28:11 ON 27 MAR 2007

L3 10 S L2

FILE 'REGISTRY' ENTERED AT 08:40:34 ON 27 MAR 2007

L4 STRUCTURE UPLOADED

L5 135 S L4 FULL SUB=L2

FILE 'CAPLUS' ENTERED AT 08:41:00 ON 27 MAR 2007

L6 6 S L5

FILE 'REGISTRY' ENTERED AT 10:40:40 ON 27 MAR 2007

L7 STRUCTURE UPLOADED

=> s l7 full sub=l2

FULL SUBSET SEARCH INITIATED 10:41:01 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L8 0 SEA SUB=L2 SSS FUL L7

=> log h

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

41.10

339.77

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-12.48

Karen Cheng